Wells Fargo Sticks to Their Buy Rating for Becton Dickinson (BDX)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Becton Dickinson (BDXResearch Report) yesterday. The company’s shares closed yesterday at $240.69.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 18.3% and a 69.7% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Intuitive Surgical, and Johnson & Johnson.

Becton Dickinson has an analyst consensus of Strong Buy, with a price target consensus of $278.80, a 15.8% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $250 price target.


See today’s analyst top recommended stocks >>

Based on Becton Dickinson’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4.4 billion and GAAP net loss of $135 million. In comparison, last year the company earned revenue of $3.17 billion and had a net profit of $327 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.